These activating mutations, which occur in up to 50% of NSCLC patients, result in ligand-independent downstream signaling of EGFR, promoting increased malignant cell survival, proliferation, invasion, and metastasis [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.